Purpose: This multicenter, double-blind, placebo-controlled crossover study evaluated the efficacy of a new oral contraceptive (OC) formulation containing drospirenone 3 mg and ethinyl estradiol (EE) 20 mug in treating symptoms of premenstrual dysphoric disorder (PMDD).
Method: The OC formulation or placebo was administered for 24 days in a 28-day cycle (24/4), rather than the usual 21-day active treatment, 7-day inert-pill regimen. Participants (N=64) were randomized to either study treatment for three cycles and then after a washout period of one treatment-free cycle switched to the alternate treatment.
Results: The mean decrease from baseline for total Daily Record of Severity of Problems (DRSP) scores while using drospirenone/EE was significantly greater than for placebo (-12.47, 95% CI=-18.28, -6.66; p<.001). A positive response (i.e., a score of 1 or 2 in the Clinical Global Impressions-Improvement scale) occurred in 61.7% and 31.8% of subjects while taking drospirenone/EE and placebo, respectively (p=.009).
Conclusion: Drospirenone/EE, given in a 24/4 regimen, was superior to placebo for improving symptoms associated with PMDD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.contraception.2005.08.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Emotion regulation-based internet-delivered cognitive behavioural therapy for premenstrual dysphoric disorder: study protocol for a randomised controlled trial in Sweden.
BMJ Open
January 2025
Department of Psychology, Uppsala Universitet, Uppsala, Sweden.
Introduction: Premenstrual dysphoric disorder (PMDD) is a cyclic mood disorder affecting around 2%-5% of women of reproductive age. Pharmacological interventions exist, but many patients with PMDD experience residual symptoms, discontinue medications or refrain from them due to side effects. Thus, non-pharmacological treatments are needed as an alternative or additive treatment strategy.
View Article and Find Full Text PDFOverlooked consequences of undiagnosed Premenstrual Dysphoric Disorder in Pakistani women.
J Pak Med Assoc
January 2025
2nd Year MBBS Student, Ziauddin University, Karachi, Pakistan.
Association between adverse childhood experiences and menstruation-related symptoms among Japanese female workers: A cross-sectional study.
Child Abuse Negl
January 2025
Department of Mental Health, Graduate School of Medicine, The University of Tokyo, 7-3-1, hongi, Bunkyo-ku, Tokyo 113-0033, Japan.
Backgrounds: Menstruation-related symptoms are a common and serious health problem even without a specific diagnosis such as premenstrual dysphoric mood disorder (PMDD) or dysmenorrhea. Various adverse childhood experiences (ACEs) might be associated with menstruation-related symptoms, not only traditional traumatic events such as abuse, but also expanded ACEs such as childhood poverty, school bullying, or natural disasters.
Objective: This study examined the association between expanded ACEs (ACEs for Japanese) and menstruation-related symptoms among Japanese working women.
Improving care experiences for premenstrual symptoms and disorders in the United Kingdom (UK): a mixed-methods approach.
BMC Health Serv Res
January 2025
Cambridge Centre for Neuropsychiatric Research, Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
Background: Poor care experiences are reported for premenstrual disorders, which may result in negative outcomes such as distress, reduced healthcare engagement, and delays to diagnosis. This research aimed to explore healthcare experiences for premenstrual symptoms in the United Kingdom and identify areas for potential improvements based on participant responses.
Method: An online survey was delivered, with participants recruited via social media.
Psychological stress dysfunction in women with premenstrual syndrome.
Heliyon
November 2024
Mental Health Education Center, Xidian University, Xi'an, China.
Premenstrual syndrome (PMS) encompasses a range of emotional, physiological, and behavioral symptoms that occur during the luteal phase of the menstrual cycle (MC) and resolve with the onset of menstruation. These symptoms, which can include fatigue, physical pain, anxiety, irritability, and depression, significantly affect women's daily lives and overall well-being. In severe cases, PMS can progress to premenstrual dysphoric disorder (PMDD), profoundly impairing quality of life.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!